The development of pharmaceutical products requires the determination of relevant pharmacokinetic properties of drugs and compounds candidate to be drugs.

With the objective of promoting the design of new compounds with good bioavailability and therapeutic efficacy in diverse areas, such as Alzheimer’s, cancer or others, MolDrug has developed a computational platform, ProtoPRED. It allows the prediction of a wide range of pharmacokinetic properties of chemical compounds, in a fast and user-friendly way. The platform provides the QMRF and QPRF reports required for registration purposes.

ProtoADME is available as part of ProtoPRED platform.